Similar articles

• Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.

  Halasa NB, Shankar SM, Talbot TR, Arbogast PG, Mitchel EF, Wang WC, Schaffner W, Craig AS, Griffin MR. Halasa NB, et al. Clin Infect Dis. 2007 Jun 1;44(11):1428-33. doi: 10.1086/516781. Epub 2007 Apr 18. Clin Infect Dis. 2007. PMID: 17479937
• Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines.

  Picazo JJ. Picazo JJ. Clin Microbiol Infect. 2009 Apr;15 Suppl 3:4-6. doi: 10.1111/j.1469-0691.2009.02723.x. Clin Microbiol Infect. 2009. PMID: 19366362 Review.
• Promises and challenges of pneumococcal conjugate vaccines for the developing world.

  Grijalva CG, Edwards KM. Grijalva CG, et al. Clin Infect Dis. 2006 Sep 15;43(6):680-2. doi: 10.1086/506945. Epub 2006 Aug 4. Clin Infect Dis. 2006. PMID: 16912938 No abstract available.
• A fatal pneumococcal infection in a vaccinated 9-year-old child with sickle cell disease.

  Babiker MA, Kambal AM, Chowdhury MN. Babiker MA, et al. Trop Geogr Med. 1986 Sep;38(3):299-300. Trop Geogr Med. 1986. PMID: 3750399
• The coming of age of niche vaccines? Effect of vaccines on resistance profiles in Streptococcus pneumoniae.

  McGee L. McGee L. Curr Opin Microbiol. 2007 Oct;10(5):473-8. doi: 10.1016/j.mib.2007.08.008. Epub 2007 Oct 23. Curr Opin Microbiol. 2007. PMID: 17936680 Review.